Abstract
The latest data from the World Health Organization suggest that hepatitis C virus (HCV) infection is a leading cause of liverrelated mortality. Moreover, HCV results in extra-hepatic manifestations of the infection and metabolic disorders. In addition to that, we observe an increasing incidence of metabolic syndrome in the general population. Insulin resistance and/or impaired glucose metabolism are the key components in the pathogenesis of both HCV infection and metabolic syndrome with metabolicassociated fatty liver disease (MAFLD) as one of its manifestations. Patients with chronic hepatitis C and MAFLD have a higher risk of severe fibrosis and hepatocellular carcinoma. Direct-acting antiviral agents (DAAs) are currently available for the treatment of HCV infection in adults and children aged 3 years and older. Steatosis might have a negative impact on the treatment outcome in HCV patients; however, this correlation has not yet been sufficiently studied. Key words: insulin resistance, MAFLD, metabolic syndrome, chronic hepatitis C
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
